Case reports in ophthalmology

Sudden One-Sided Vision Loss After Using Tirzepatide: A Case Report

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

Dual receptor agonists like tirzepatide have advanced the management of type 2 diabetes and obesity.

  • GIP and GLP-1 receptor agonists are associated with improved glycemic control and weight loss in individuals with type 2 diabetes.
  • Concerns have been raised regarding potential rare ocular adverse events linked to these treatments.
  • Further investigation is needed to clarify the safety profile of tirzepatide and similar medications.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Feb '26
Eye Health Outcomes with Tirzepatide Compared to GLP-1 Drugs in Type 2 Diabetes
top 5% journal
cited by 5 papers
journal article
Jan '26
Possible Link Between Tirzepatide and Sudden Optic Nerve Damage: Evidence from Safety Reports and Search Trends
cited by 1 paper
journal article
May '22
Using tirzepatide, a drug that activates two hormone receptors, to manage type 2 diabetes: a combined review and analysis
top 2% journal
cited by 236 papers
systematic review
Aug '25
Semaglutide or Tirzepatide and Nerve and Vision Problems in Type 2 Diabetes
top 2% journal
cited by 51 papers
journal article
Apr '26
Sudden development of new abnormal blood vessels in the eye after starting tirzepatide
top 50% journal
cited by 1 paper
case reports
Mar '26
Eye problems linked to glucagon-like peptide-1 receptor agonist medicines: Clinical findings and understanding
top 30% journal
journal article
Oct '25
Tirzepatide treatment for adults with obesity
cited by 3 papers
systematic review

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #59
GLP-1 drugs linked to fewer psychiatric hospitalizations in schizophrenia patients with diabetes
5 days ago7 studies
issue #58
A new triple receptor drug cut body weight by nearly 20% in 24 weeks
1 week ago7 studies
issue #57
A triple-receptor obesity drug just posted 25–35% weight loss in a phase 3 trial
2 weeks ago7 studies
issue #56
Semaglutide cut heart attack risk by 20% — but weight loss explains less than half of it
3 weeks ago7 studies
issue #55
The brain circuit that makes GLP-1 drugs work also causes nausea — and they can't be separated
4 weeks ago7 studies
issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 weeks ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
6 weeks ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
7 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
8 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief